Selective Repression of RET Proto-oncogene in Medullary Thyroid Carcinoma by a Natural Alkaloid Berberine

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Aug 27

PMID 26307103

Citations 14

Authors

Vishnu Muthuraj Kumarasamy

Yoon-Joo Shin

John White

Daekyu Sun

Affiliations

Soon will be listed here.

Abstract

Background: The gain-of-function mutation of the RET proto-oncogene, which encodes a receptor tyrosine kinase, is strongly associated with the development of several medullary thyroid carcinomas (MTCs). Thus, the RET protein has been explored as an excellent target for progressive and advanced MTC. In this study we have demonstrated a therapeutic strategy for MTC by suppressing the transcription of RET proto-oncogene though the stabilization of G-quadruplex structure formed on the promoter region of this gene using a natural product berberine.

Methods: Medullary thyroid carcinoma (MTC) TT cell line has been used to evaluate the effects of berberine on RET expression and its downstream signaling pathways. The specificity of berberine was demonstrated by using the papillary thyroid carcinoma TPC1 cell line, which lacks the G-quadruplex forming sequence on the RET promoter region due to chromosomal rearrangement.

Results: Berberine suppressed the RET expression by more than 90 % in MTC TT cells at a concentration of 2.5 μg/ml with minimal effect on the TPC1 cells. Canadine, which is a structural analogue of berberine, showed little interaction with RET G-quadruplex and also had no effect on RET expression in MTC TT cells. The down-regulation of RET with berberine further inhibited the cell proliferation through cell cycle arrest and activation of apoptosis in TT cells, which was confirmed by a 2-fold increase in the caspase-3 activity and the down-regulation of cell-cycle regulatory proteins.

Conclusion: Our data strongly suggest that the G-quadruplex forming region and the stabilization of this structure play a critical role in mediating the repressive effect of berberine on RET transcription.

Citing Articles

A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.

Alqahtani T, Alsubait A, Aloumi M, Alamer A, Alomari G, Alwassil O BMC Cancer. 2024; 24(1):1569.

PMID: 39716145 PMC: 11665027. DOI: 10.1186/s12885-024-13345-9.

Promising Role of Alkaloids in the Prevention and Treatment of Thyroid Cancer and Autoimmune Thyroid Disease: A Comprehensive Review of the Current Evidence.

Di Dalmazi G, Giuliani C, Bucci I, Mascitti M, Napolitano G Int J Mol Sci. 2024; 25(10).

PMID: 38791433 PMC: 11121374. DOI: 10.3390/ijms25105395.

Canadine inhibits epithelial mesenchymal transformation of HPV-negative cervical cancer.

Ma Y, Yang Q, Gu D, Yuan X, Wang Y, Guo L Tissue Barriers. 2023; 12(3):2256641.

PMID: 37819188 PMC: 11262239. DOI: 10.1080/21688370.2023.2256641.

Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways.

Almatroodi S, Alsahli M, Rahmani A Molecules. 2022; 27(18).

PMID: 36144625 PMC: 9505063. DOI: 10.3390/molecules27185889.

Berberine as a Potential Anticancer Agent: A Comprehensive Review.

Rauf A, Abu-Izneid T, Khalil A, Imran M, Shah Z, Emran T Molecules. 2021; 26(23).

PMID: 34885950 PMC: 8658774. DOI: 10.3390/molecules26237368.

References

Guo K, Pourpak A, Beetz-Rogers K, Gokhale V, Sun D, Hurley L . Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. J Am Chem Soc. 2007; 129(33):10220-8. PMC: 2566970. DOI: 10.1021/ja072185g. View

Runeberg-Roos P, Saarma M . Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med. 2007; 39(8):572-80. DOI: 10.1080/07853890701646256. View

Lodish M, Stratakis C . RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008; 8(4):625-32. PMC: 2670186. DOI: 10.1586/14737140.8.4.625. View

Correche E, Andujar S, Kurdelas R, Gomez Lechon M, Freile M, Enriz R . Antioxidant and cytotoxic activities of canadine: biological effects and structural aspects. Bioorg Med Chem. 2008; 16(7):3641-51. DOI: 10.1016/j.bmc.2008.02.015. View

Ma Y, Ou T, Hou J, Lu Y, Tan J, Gu L . 9-N-Substituted berberine derivatives: stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg Med Chem. 2008; 16(16):7582-91. DOI: 10.1016/j.bmc.2008.07.029. View

Schweppe R, Klopper J, Korch C, Pugazhenthi U, Benezra M, Knauf J . Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008; 93(11):4331-41. PMC: 2582569. DOI: 10.1210/jc.2008-1102. View

Pitt S, Chen H . The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery. 2008; 144(5):721-4. PMC: 3245622. DOI: 10.1016/j.surg.2008.06.028. View

Ahmadian S, Barar J, Saei A, Abolghassemi Fakhree M, Omidi Y . Cellular toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J Vis Exp. 2009; (26). PMC: 2791085. DOI: 10.3791/1191. View

Sun D, Guo K, Shin Y . Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor gene. Nucleic Acids Res. 2010; 39(4):1256-65. PMC: 3045601. DOI: 10.1093/nar/gkq926. View

10.

Ma Y, Ou T, Tan J, Hou J, Huang S, Gu L . Quinolino-benzo-[5, 6]-dihydroisoquindolium compounds derived from berberine: a new class of highly selective ligands for G-quadruplex DNA in c-myc oncogene. Eur J Med Chem. 2011; 46(5):1906-13. DOI: 10.1016/j.ejmech.2011.02.020. View

11.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

12.

Houvras Y . Completing the Arc: targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol. 2011; 30(2):200-2. DOI: 10.1200/JCO.2011.38.7639. View

13.

Park K, Kim J, Bae J, Park S, Jee H, Lee K . Berberine inhibited the growth of thyroid cancer cell lines 8505C and TPC1. Yonsei Med J. 2012; 53(2):346-51. PMC: 3282951. DOI: 10.3349/ymj.2012.53.2.346. View

14.

Bessi I, Bazzicalupi C, Richter C, Jonker H, Saxena K, Sissi C . Spectroscopic, molecular modeling, and NMR-spectroscopic investigation of the binding mode of the natural alkaloids berberine and sanguinarine to human telomeric G-quadruplex DNA. ACS Chem Biol. 2012; 7(6):1109-19. DOI: 10.1021/cb300096g. View

15.

Gavrilov K, Saltzman W . Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012; 85(2):187-200. PMC: 3375670. View

16.

Fournier N, Lee B, Banasr M, Elsayed M, Duman R . Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology. 2012; 63(4):642-52. PMC: 3392414. DOI: 10.1016/j.neuropharm.2012.04.033. View

17.

Balogh K, Asa S, Zheng L, Cassol C, Cheng S, Ezzat S . The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression. Oncogene. 2011; 31(36):4012-21. PMC: 3954818. DOI: 10.1038/onc.2011.569. View

18.

Chau N, Haddad R . Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res. 2012; 19(3):524-9. DOI: 10.1158/1078-0432.CCR-12-2353. View

19.

Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C . Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013; 377(1-2):1-6. DOI: 10.1016/j.mce.2013.06.025. View

20.

Bidzinska J, Cimino-Reale G, Zaffaroni N, Folini M . G-quadruplex structures in the human genome as novel therapeutic targets. Molecules. 2013; 18(10):12368-95. PMC: 6270421. DOI: 10.3390/molecules181012368. View